Contracts & Grants

Information is courtesy of the Office of Sponsored Projects. Each listing includes the faculty member's name and school(s) appointments at The University of Texas Health Science Center at Houston, contracting or granting agency, funding amount and project title.

New

Michael R. Blackburn, Medical School (MS) and Graduate School of Biomedical Sciences (GSBS), Enzon Pharmaceuticals, $54,718, Analysis of Human PEG-ADA in Adenosine Deaminase Deficient Mice; and Enzon Pharmaceuticals, $64,591, Efficacy of Adenosine Deaminse Enzyme Therapy in the Treatment of Bleomycin-Induced Pulmonary Fibrosis.

Kamal F. Busaidy, Dental Branch, Oral and Maxillofacial Surgery Foundation, $10,000, Faculty Educator Development Award.

Florence J. Dallo, School of Public Health (SPH), Robert Wood Johnson Foundation, $50,046, Racial and Ethnic Differences in the Quality of Care of Immigrants and Non-Immigrants.

Barry R. Davis, SPH, National Institutes of Health (NIH), $887,920, Training Program in Biostatistics at UT Health Science Center at Houston-SPH.

Linda Ewing-Cobbs, MS, University of Houston, $55,079, Cognitive, Instructional and Neuroimaging Factors in Math.

Michael E. Fant, MS and GSBS, NIH, $330,261, PLAC1 in Placental Development.

Mauro Ferrari, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) and GSBS, National Aeronautics & Space Administration, $3,695,926, Nanotechnology for Space Medicine.

Susan Gunnewig, MS, Texas Education Agency, $200,000, Professional Development and Technical Assistance for Prekindergarten Expansion Grantees.

Khader M. Hasan, MS and GSBS, NIH, $1,202,852, Diffusion Tensor Imaging of Wallerian Degeneration in MS.

Adelaide A. Hebert, MS, Nucryst Pharmaceuticals Inc., $46,020, An Open-Label Treatment Continuation Study of 2% Nanocrystalline Silver Cream (NPI 32101) Applied Twice Daily in Children with Atopic Dermatitis who Previously Completed a Double-Blind, Placebo-Controlled Study of NPI 32101.

Barry D. Kahan, MS and GSBS, Novartis Pharmaceuticals Corp., $116,939, A 12-Month Open-Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AIB071 plus Tacrolimus (Converted to Myfortic after 3 Months), Vs. Myfortic plus Tacrolimus in De Novo Renal Transplants Recipients.

Susan Landry, MS, Oregon Research Institute, $5,560, First Time Parents Interactive Parenting Intervention; and Texas Workforce Commission, $8,300,000, Texas Early Education Model $8.3 Million.

Jary M. Lesser, MS, Myriad Pharmaceuticals Inc., $176,280, Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer’s Type; Quintiles Inc., $222,019, A Double-Blind Placebo-Controlled Study of VP-4896 for the Treatment of Mild-to-Moderate Alzheimer’s Disease; and Neurochem Inc., $94,350, An Open-Label Extension of the Phase III Study CL- 758007 Alzhemed in Patients with Alzheimer’s Disease.

Hualou Liang, School of Health Information Sciences and GSBS, NIH, $705,841, Attention Related Ensemble Activity in Visual Cortex.

John W. Lindsey, MS and GSBS, Serono Inc., $72,800, Epstein-Barr Virus and Multiple Sclerosis.

Owen Eugene McCormack, MS, PPD Development, LP, $30,030, A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 Infected, Treatment-Naive Subjects with a 12-Week Extension Treatment.

Barbara E. Murray, MS and GSBS, Johnson & Johnson, $28,600, High Level, Type A Beta-Lactamase Production among Staphylococcus Aureus Strains from Serious Infections.

John D. Reveille, MS and GSBS, NIH, $6,527,063, Genetics and Ankylosing Spondylitis Pathogenesis.

Michael W. Ross, SPH, The University of Texas Southwestern Medical Center, $10,873, STD/HIV Prevention Training Centers - Part II.

Richard W. Smalling, MS, Abbott Vascular Inc., $80,000, The Emboshield and Xact Post Approval Carotid Stent Trial, The Exact Study.

Latisha A. Smith, MS, King Pharmaceuticals Research and Development, $48,000, A Multicenter, Double-Blind, Randomized, Parallel, Vehicle and Standard Care Controlled, Dose-Ranging Study Assessing the Safety and Efficacy of MRE0094 Gel when Applied Topically for 90 Days to Subjects with Diabetic, Neuropathic Foot Ulcers.

Stephen C. Waring, SPH, Texas Council on Alzheimer’s Disease and Related Disorders, $111,939, Research Epidemiologist for the Texas Consortium of Alzheimer’s Disease Centers.

Robert Joseph Yetman, MS, Merck & Co. Inc., $107,700, An Open, Randomized, Multicenter Study of the Safety, Tolerability and Immunogenicity of Vaqta Given Concomitantly with Proquad and Prevnar in Healthy Children 12 Months of Age.

Renewal

Andrew Bean, MS and GSBS, NIH, $1,560,813, Molecular Mechanisms of Endocytosis.

Christine A. Brosnan, School of Nursing (SON), Health Resources and Services Administration (HRSA), $107,215, Advanced Education Nursing Traineeships.

Gloria P. Heresi, MS, Westat Inc., $63,914, Longitudinal Epidemiologic Study to Gain Insight into HIV and AIDS in Children and Youth (Legacy).

Rodney C. Lester, HRSA, $6,302, Nurse Anesthetist Traineeship.

Frederick A. Moore, MS, NIH, $1,609,308, Role of the Gut in Post- Injury Multiple Organ Failure.

Guy S. Parcel, SPH, HRSA, $101,355, Public Health Traineeships.

Rick A. Wetsel, IMM and GSBS, NIH, $1,417,320, Complement Anaphylatoxin Receptors in Inflamation.

Supplemental

Ambro Van Hoof, MS and GSBS, NIH, $1,219,872, Metabolism of Yeast MRNAs that Lack a Stop Codon.

Richard W. Smalling, MS, Aga Medical Corporation, $304,000, Randomized Evaluation of Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (Respect) Trial.